By Nina Kienle
Almirall and Etherna plan to collaborate to develop mRNA-based therapies in medical dermatology.
Spain-based pharmaceutical company Almirall said on Tuesday that the collaboration looks to combine its expertise in the dermatology space with Etherna’s proprietary messenger RNA–or mRNA–and lipid nanoparticle technology. The companies hope to accelerate the discovery of therapies for severe skin diseases including non-melanoma skin cancer.
Almirall is set to lead clinical development and commercialization.
Belgium-based life-sciences company Etherna, which specializes in mRNA products, is eligible to receive development and commercial milestone payments that could exceed 300 million euros ($323 million) contingent upon launch and commercial success of multiple products, as well as royalties based on future global sales, Almirall said.
Write to Nina Kienle at [email protected]
Read the full article here